RELATED CONTENT
July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...
July 25, 2024 
According to research conducted by Polaris Market Research, the global positron emission tomography (PET)/computed ...
January 17, 2024 
March 21, 2023 — Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical ...
March 21, 2023 Positron Corporation entered into a multi-year radioisotope supply agreement with iThemba LABS of Cape Town, South Africa. The supply agreement contracts the procurement of raw material, strontium-82 (Sr-82) from iThemba LABS for further production of the active pharmaceutical ingredient (API) at Positron's radioisotope production facility in Lubbock, Texas. In September 2013, Positron will receive relevant volumes of strontium-82 for qualification and will commence with commercial availability beginning in February 2014. This additional supply will enhance the industry's strontium-82 supply and increase the availability of radiopharmaceuticals to the end user. Positron intends to make this Sr-82 API supply available to all rubidium-82 generator producers in the marketplac
August 09, 2013 
Positron Corp. announced the release of the PosiRx 3000-Series, its latest pharmacy automation systems. The PosiRx 3000-Series are the first systems to automate and encompass the complete compounding process, from generator elution to dose distribution, of multiple diagnostic SPECT agents in an environment engineered to be ISO Class 5 and USP 797 compliant. Designed for facilities dispensing as many as 300 patient-specific doses per day, the PosiRx 3000-Series will benefit providers and patients by enabling unit dose radiopharmaceuticals to be prepared more cost effectively and accurately than previously possible.
May 16, 2013 September 12, 2012 – Positron Corp. announced that Jubilant DraxImage Inc., a Jubilant Life Sciences Company, and Positron have executed a Letter of Intent pertaining to Positron's supply of Active Pharmaceutical Ingredient (API) grade Sr-82 for the JDI Sr-82/Rb-82 generator; JDI's and Positron's co-promotion of JDI Sr-82/Rb-82 generators to end-users (upon FDA clearance); and Positron's lifecycle management for expired JDI Sr-82/Rb-82 generators.
September 12, 2012 
August 27, 2012 — Positron Corp., a molecular imaging healthcare company, announced the submission of a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for the production of active pharmaceutical ingredient- (API) grade strontium-82 through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT).
August 27, 2012 August 21, 2012 — The U.S. Food and Drug Administration (FDA) granted marketing approval for cfrQuant, coronary flow reserve (CFR) quantification software from the University of Texas Health Science Center at Houston (UTHealth).
August 21, 2012 
August 20, 2012 — Positron Corp. announced the use of its Attrius system at Caring Heart and Brain Imaging Inc. of Manasquan, N.J., which now offers amyvid positron emission tomography (PET) scans to identify the presence of plaque in the brain.
August 20, 2012 August 14, 2012 — Positron Corp. announced the transfer, consolidation and integration of its radiopharmaceutical operations from the Crown Point, Ind. facility to its Lubbock, Texas site.
August 14, 2012